The experimental study of simvastatin on improving aspirin resistance in diabetic rats

doi:10.13459/j.cnki.cjap.2016.05.003

Abstract

Abstract: Objective: The purpose of the present study was to investigate the effects of the combination of aspirin, simvastatin in diabetic rat on platelet function.Methods: Eight-week-old male Wistar rats were selected and randomly divided into diabetic group (n=48) and normal control group (n=48). Diabetic rats were injected with 1% STZ (65mg/kg, dissolved in 0.l mmol/L, pH 4.5 citrate buffer) to induce diabetic model and the rats in normal control group were injected with the same dose of citrate buffer. A rat with blood glucose greater than 16.8 mmol/L and along with diabetic symptoms of polydipsia, polyuria and weight loss was considered the successful model of diabetes. Diabetic rats and normal Wistar rats were randomly divided into 4 groups and given aspirin(10 mg/kg), simvastatin(2 mg/kg), combination of aspirin(10mg/kg) and simvastatin(2 mg/kg), PBS for 8 weeks, respectively. The platelet function and the expression of CD62P were evaluated. The levels of nitric oxide (NO), endothelin (ET), thromboxane B2(TXB2), prostacyclin (PGI2), adiponectin (APN), TXB2 were detected in the serum. The expressions of heme oxygenase-1(HO-1), HO-2, endothelial nitric oxide synthase(e-NOS), p-eNOS, B-cell lymphoma-2(Bcl-2), cyclooxygenase-2(COX-2) in thoracic aorta were evaluated by Western blot.Results: Compared with control rats, diabetic rats had high platelet aggregation and activation (P<0.05), which treated aspirin also showed lower aspirin sensitivity (P<0.05). The combination of drugs upregulated the expression of HO-1, eNOS, p-eNOS, BCL-2, APN levels and decreased the expression of COX-2, and had a greater inhibitory effect on platelet aggregation and activation. The combination of drugs improved endothelial function, adjusted TXA2/PGI2 levels and increased NO levels, which resulted in a great potential antiplatelet effect.Conclusion: These results suggest that simvastatin may improvethe effect of aspirin on anti-platelet function in diabetic rats.

Key words: simvastatin, diadetes, platelet resistance, rat

HAO Wei-jun, KE Se-zhang, LIU Lin, LI Jian-hua, LUO Xiao-xing, SUN Yu-fa, CAO Jian, FAN Li. The experimental study of simvastatin on improving aspirin resistance in diabetic rats[J]. CJAP, 2016, 32(5): 395-400.

References

[1] Floyd CN, Ferro A. Mechanisms of aspirin resistance[J]. Pharmacol Ther, 2014, 141(1):69-78.
[2] Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus[J]. Diabetologia, 2008, 51(3):385-390.
[3] Ertugrul DT, Tutal E, Yildiz M, et al.Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010, 95(6):2897-2901.
[4] Sacco M, Pellegrini F, Roncaglioni MC, et al.Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients:results of the Primary Prevention Project (PPP) trial[J]. Diabetes Care, 2003, 26(12):3264-3272.
[5] Sacco M, Pellegrini F, Roncaglioni MC, et al.Rosuvastatin reduces platelet activation in heart failure:role of NO bioavailability[J]. ArteriosclerThromb Vasc Biol, 2005, 25(5):1071-1077.
[6] King AJ. The use of animal models in diabetes research[J]. Br J Pharmacol, 2012, 166(3):877-894.
[7] Laing SP, Swerdlow AJ, Carpenter LM, et al.Mortality from cerebrovascular disease in a cohort of 23000 patients with insulin-treated diabetes[J]. Stroke, 2003, 34(2):418-421.
[8] Watala C, Ulicna O, Golanski J, et al.High glucose contributes toaspirin insensitivity in streptozotocin-diabetic rats:a multiparametric aggregation study[J]. Blood Coagul Fibrinolysis, 2006, 17(2):113-124.
[9] Ajjan R, Grant PJ. Coagulation and atherothrombotic disease[J]. Atherosclerosis, 2006, 186(2):240-259.
[10] Dunn EJ, Philippou H, Ariëns RA, et al.Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus[J]. Diabetologia, 2006, 49(5):1071-1080.
[11] Watala C, Boncler M, Gresner P. Blood platelet abnormalities andpharmacological modulation of platelet reactivity in patients with diabetes mellitus[J]. Pharmacol Rep, 2005, 57 Suppl:42-58.
[12] Renna NF, Vazquez MA, Lama MC, et al.Effect of chronic aspirin administration on an experimental model of metabolic syndrome[J]. Clin Exp Pharmacol Physiol, 2009, 36(2):162-168.
[13] Kunieda Y, Nakagawa K, Nishimura H, et al.HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin Ⅱ in cultured rat aortic endothelial cells[J]. ThrombRes, 2003, 110(4):227-234.
[14] Shao H, Shen Y, Liu H, et al.Simvastatin suppresses lung inflammatory response in a rat cardiopulmonary bypass model[J]. Ann Thorac Surg, 2007, 84(6):2011-2018.
[15] Leytin V, Mody M, Semple JW, et al.Flow cytometric parameters for characterizing platelet activation by measuring P-selectin (CD62) expression:theoretical consideration and evaluation in thrombin-treated platelet populations[J].Biochem Biophys Res Commun, 2000, 269(1):85-90.
[16] Remuzzi G, Benigni A, Dodesini P, et al.Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect[J]. J ClinInvest, 1983, 71(3):762-768.